Research News

---

Topic: Diagnosis (view all topics)

Tags for topic Diagnosis:

• 1cm-1.9cm
• Ductal Carcinoma In Situ
• Early-stage: Stage 0 -- DCIS (Ductal Carcinoma in Situ)
• Early-stage: Stage IA
• Early-stage: Stage IB
• Early-stage: Stage IIA
• Early-stage: Stage IIB
• Early-stage: Stage IIIA
• Estrogen Receptor Negative Cancer
• Estrogen Receptor Positive Cancer
• HER2/neu Negative Cancer
• HER2/neu Positive Cancer
• HER2 Overexpressing
• Invasive or Infiltrating Ductal Carcinoma
• Invasive or Infiltrating Lobular Carcinoma
• Less than 1cm
• Locally Advanced-stage: Stage IIIB
• Locally Advanced-stage: Stage IIIC
• Luminal A
• Luminal B
• Metastatic
• Metastatic/Advanced-stage: Stage IV
• Non-Metastatic
• Progesterone Receptor Negative Cancer
• Progesterone Receptor Positive Cancer
• Regional
• Triple Negative

View articles by month and year

• More Younger Women Being Diagnosed with Metastatic Breast Cancer

  Published on February 28, 2013 at 3:15 am

  • Tags: Metastatic/Advanced-stage: Stage IV, Diet, Environmental Factors, and Exercise

  During the past 30 years, more women age 25 to 39 were diagnosed with metastatic breast cancer.

• Women Who Start Treatment More Than 60 Days After Diagnosis of Advanced-Stage Disease Have Worse Survival

  Published on January 31, 2013 at 4:15 am

  • Tags: Metastatic and Metastatic/Advanced-stage: Stage IV

  A study has found that women diagnosed with advanced-stage breast cancer who wait more than 60 days to start treatment have a much higher risk of dying from breast cancer than women who start treatment earlier.

• PET/CT Improves Staging in Patients with Locally Advanced Breast Cancer

  Published on January 25, 2013 at 6:29 am

  • Tags: Locally Advanced-stage: Stage IIIB and Locally Advanced-stage: Stage IIIC

  PET/CT can provide more accurate information than conventional imaging tests for staging locally advanced breast cancer.

• Triple-Negative Breast Cancer Seems to Have Abnormal Genes That May Be Treatment Targets

  Published on December 16, 2012 at 5:31 am

  • Tags: Triple Negative, Estrogen Receptor Negative Cancer, HER2/neu Negative Cancer, and Progesterone Receptor Negative Cancer

  A small study has found that many triple-negative breast cancers have abnormal genes that could be targeted by medicines already on the market or being developed.

• Quality Personal Relationships Boost Survival in Women Diagnosed with Early-Stage Breast Cancer

  Published on November 17, 2012 at 12:00 am

  • Tags: Early-stage: Stage 0 -- DCIS (Ductal Carcinoma in Situ), Early-stage: Stage IA, Early-stage: Stage IB, Early-stage: Stage IIA, Early-stage: Stage IIB, Early-stage: Stage IIIA, and Support Groups

  A study suggests that the quality of a woman’s social networks seems to be just as important as the size of the social networks in predicting breast cancer survival.

• Mammostrat Test Helps Estimate Recurrence Risk and Make Treatment Decisions

  Published on October 16, 2012 at 12:00 am

  • Tags: Early-stage: Stage 0 -- DCIS (Ductal Carcinoma in Situ), Early-stage: Stage IA, Early-stage: Stage IB, Early-stage: Stage IIA, Early-stage: Stage IIB, Early-stage: Stage IIIA, Estrogen Receptor Positive Cancer, and Progesterone Receptor Positive Cancer

  A study shows that the Mammostrat test can offer more information on the risk of early-stage, hormone-receptor-positive breast cancer coming back in postmenopausal women and help make treatment decisions.

• Regular Screening Helps Reduce Difference in Breast Cancer Outcomes Between African American and White Women

  Published on September 29, 2012 at 12:00 am

  • Tags: Mammography

  A study suggests that regular screening mammograms can help improve the outcomes of African American women diagnosed with breast cancer.

• Study Analyzes Breast Cancer Genetics, Finds Four Classes of Disease

  Published on September 25, 2012 at 12:00 am

  • Tags: Early-stage: Stage 0 -- DCIS (Ductal Carcinoma in Situ), Early-stage: Stage IA, Early-stage: Stage IB, Early-stage: Stage IIA, Early-stage: Stage IIB, Early-stage: Stage IIIA, Estrogen Receptor Negative Cancer, Estrogen Receptor Positive Cancer, HER2/neu Negative Cancer, HER2/neu Positive Cancer, Progesterone Receptor Negative Cancer, Progesterone Receptor Positive Cancer, Luminal A, Luminal B, Triple Negative, and HER2 Overexpressing

  Researchers have done the most thorough analysis of breast cancer genetics to date and found that there are four genetically distinct classes of the disease.

• FDA Advisory Panel Approves MarginProbe System

  Published on June 26, 2012 at 12:00 am

  • Tags: Ductal Carcinoma In Situ, Invasive or Infiltrating Ductal Carcinoma, Early-stage: Stage 0 -- DCIS (Ductal Carcinoma in Situ), Early-stage: Stage IA, Early-stage: Stage IB, Early-stage: Stage IIA, Early-stage: Stage IIB, Early-stage: Stage IIIA, Lumpectomy, Non-Metastatic, and Invasive or Infiltrating Lobular Carcinoma

  An FDA expert panel voted to approve the MarginProbe system - a device that helps surgeons decide if all the cancer tissue has been removed during lumpectomy.

• Breast Cancer’s Hormone Receptor and HER2 Status Can Change After Diagnosis

  Published on June 20, 2012 at 12:00 am

  • Tags: Locally Advanced-stage: Stage IIIB, Locally Advanced-stage: Stage IIIC, Metastatic/Advanced-stage: Stage IV, Progesterone Receptor Negative Cancer, Progesterone Receptor Positive Cancer, Estrogen Receptor Negative Cancer, Estrogen Receptor Positive Cancer, HER2/neu Positive Cancer, Metastatic, Non-Metastatic, Regional, Biopsy, FISH Test, IHC Test, Inform HER2 Dual ISH Test, SPoT-Light HER2 CISH, HER2/neu Negative Cancer, Luminal A, Luminal B, Triple Negative, and HER2 Overexpressing

  The characteristics of a breast cancer -- including hormone receptor status and HER2 status -- can change over time. These changes may happen because the cancer cells change themselves or because treat...